Netherlands Enterprise Agency (RVO) extended an innovation credit of up to €5m to AM-Pharma for the Covid-19 trial. Credit: Gerd Altmann from Pixabay.

AM-Pharma has announced the enrolment of first participants in an exploratory cohort in Phase III REVIVAL pivotal trial of its human recombinant alkaline phosphatase (AP) for treating patients with Covid-19 and sepsis-associated acute kidney injury (SA-AKI).

The therapeutic candidate derives from two naturally occurring human isoforms of the AP enzyme.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

For the Covid-19 cohort clinical study, Dutch Ministry of Economic Affairs and Climate Policy-established Netherlands Enterprise Agency (RVO) extended an innovation credit of up to €5m to AM-Pharma.

The randomised, double-blind, placebo-controlled, two-arm, parallel-group, multi-centre trial will analyse the efficacy and safety of the compound for treating patients with SA-AKI.

The main study population will include around 1400 patients with SA-AKI. Up to 100 patients with moderate chronic kidney disease (CKD) and up to 100 patients with Covid-19 will be enrolled in two exploratory groups.

Proving the improvement in the primary endpoint of 28-day all-cause mortality, as seen in the Phase II STOP-AKI study, will form the study’s primary endpoint.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Effect of the therapy on long-term Major Adverse Kidney Events (MAKE), on the use of organ support, ICU stay length and on 90-day all-cause mortality are some of the secondary endpoints.

AM-Pharma noted that severe Covid-19 patients often have acute severe inflammation and organ failure.

According to latest studies carried out in the US, up to 90% of the Covid-19 patients who received mechanical ventilation also had AKI and its development is linked to poor prognosis.

AM-Pharma CEO Erik van den Berg said: “The prevalence of Covid-19 infections and the high AKI comorbidity support our decision to include this additional cohort into our Phase III REVIVAL pivotal study.

“By providing our proprietary recombinant alkaline phosphatase to clinicians for evaluation in severe Covid-19 cases, we aim to make our novel treatment option available for these patients.”

In July 2019, AM-Pharma raised €116m from a European syndicate of new and existing investors to support the initiation of a Phase III trial of its recombinant human alkaline phosphatase (recAP) therapeutic for patients with SA-AKI.